Compare ITIC & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ITIC | TOI |
|---|---|---|
| Founded | 1972 | 2007 |
| Country | United States | United States |
| Employees | N/A | 641 |
| Industry | Specialty Insurers | Medical/Nursing Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.8M | 579.9M |
| IPO Year | 1995 | N/A |
| Metric | ITIC | TOI |
|---|---|---|
| Price | $277.13 | $5.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 56.3K | ★ 1.8M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.43% | N/A |
| EPS Growth | ★ 13.02 | N/A |
| EPS | ★ 3.20 | N/A |
| Revenue | ★ $272,755,000.00 | N/A |
| Revenue This Year | N/A | $30.15 |
| Revenue Next Year | N/A | $25.77 |
| P/E Ratio | $85.12 | ★ N/A |
| Revenue Growth | ★ 5.60 | N/A |
| 52 Week Low | $199.16 | $2.32 |
| 52 Week High | $288.98 | $6.11 |
| Indicator | ITIC | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 65.89 | 64.43 |
| Support Level | $246.61 | $3.28 |
| Resistance Level | $284.12 | N/A |
| Average True Range (ATR) | 7.91 | 0.37 |
| MACD | -0.26 | 0.02 |
| Stochastic Oscillator | 78.37 | 78.10 |
Investors Title Co operates in the title insurance and exchange services sectors. The Company has two reportable segments. The Company's primary business activity, and one of its reportable operating segments, is the issuance of residential and commercial title insurance through ITIC and NITIC. The company's second reportable operating segment is providing tax-deferred real property exchange services through its subsidiaries, Investors Title Exchange Corporation (ITEC) and Investors Title Accommodation Corporation (ITAC).
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.